Market Overview

HitGen Extends and Expands Research Collaboration and License Agreement With MSD To Build and Screen Novel DNA-Encoded Libraries

Share:

HitGen Ltd. is pleased to announce that the company has extended and
expanded its agreement with MSD, known as Merck & Co., Inc, Kenilworth
NJ., USA into a multi-year research collaboration and license agreement
to build and screen novel DNA-encoded libraries (DELs) in order to
discover potential unique small molecule assets to be used in drug
discovery and development. Through the collaboration, HitGen and MSD
scientists will apply HitGen's advanced technology platform and research
capabilities in the design, synthesis, and screening of multiple
proprietary DELs for MSD's drug discovery efforts. In addition, HitGen
will interrogate their own DELs, consisting of hundreds of billions of
compounds, against a selected number of MSD's therapeutic targets. Novel
lead compounds from the HitGen DELs will be licensed exclusively to MSD
for further research and development. MSD will support the research at
HitGen.

"We are delighted to announce the expansion and extension of this
collaboration with MSD. Our scientists will continue to work closely
together to design and build proprietary DELs to support the discovery
of a new generation of medicines to address unmet clinical challenges.
This collaboration reflects HitGen's capabilities, expertise, and
flexibility to develop business models to meet the needs of our
collaboration partners, and provides insight into the success of our
initial target-based collaboration," said Dr. Jin Li, Chairman of the
Board and Chief Executive Officer of HitGen.

"This expanded collaboration builds upon the strong relationship we have
developed with researchers at HitGen as we apply the DEL technology
across our portfolio," said Dr. Emma Parmee, Vice President, Global
Discovery Chemistry, MSD.

About HitGen Ltd.

HitGen is an innovation driven life science company with headquarters
and main research facilities based in Chengdu, China and with laboratory
in USA. HitGen has established a unique platform for drug discovery
research. Our DNA encoded chemical libraries (DELs) contain more than
200 billion novel, diverse, drug-like compounds. These compounds are
members of DELs synthesised from many hundreds of distinct chemical
scaffolds, designed with tractable chemistry based on proven results for
identifying small molecule leads against targets from both known and
unprecedented protein classes. HitGen is collaborating with multiple
pharmaceutical, biotech and agrochemical companies, and academic
research institutes to discover and develop the therapeutics of the
future.

View Comments and Join the Discussion!